Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents

Toyoaki Hida, Ken ichi Kozaki, Hidemi Ito, Osamu Miyaishi, Yoshio Tatematsu, Takeshi Suzuki, Keitaro Matsuo, Takahiko Sugiura, Makoto Ogawa, Toshitada Takahashi, Takashi Takahashi

研究成果査読

110 被引用数 (Scopus)

抄録

This study reports that a selective COX-2 inhibitor JTE-522 inhibits both in vitro and in vivo growth of human lung cancer cells as a single agent. Furthermore, the adjunct use of JTE-522 is shown to significantly enhance treatment efficacy of conventional anticancer drugs not only in vitro but also in vivo without causing any noticeable side effects. Indeed, IC50s of various anticancer agents in vitro were reduced by up to 70%, whereas the combination therapy of JTE-522 with docetaxel and vinorelbine inhibited tumor growth in vivo by 65 and 55%, respectively. Taken together, these findings suggest that the use of a selective COX-2 inhibitor in the treatment of lung cancer may be promising, especially because of its enhancement of the treatment efficacy of conventional anticancer agents without compromising quality of life.

本文言語English
ページ(範囲)2443-2447
ページ数5
ジャーナルClinical Cancer Research
8
7
出版ステータスPublished - 2002
外部発表はい

ASJC Scopus subject areas

  • 医学一般

フィンガープリント

「Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル